Intervention Review

You have free access to this content

Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer

  1. Aramide O Lawal*,
  2. Alfred Musekiwa,
  3. Liesl Grobler

Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Published Online: 6 JUN 2013

Assessed as up-to-date: 16 MAY 2013

DOI: 10.1002/14651858.CD009620.pub2


How to Cite

Lawal AO, Musekiwa A, Grobler L. Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD009620. DOI: 10.1002/14651858.CD009620.pub2.

Author Information

  1. Stellenbosch University, Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Cape Town, Western Cape, South Africa

*Aramide O Lawal, Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 19063, Tygerberg, Cape Town, Western Cape, 7505, South Africa. aramide0319@yahoo.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 6 JUN 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Alberts 2006 {published data only}
  • Alberts DS, Hannigan EV, Liu P, Jiang C, Wilczynski S, Copeland L, Markman M. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. Gynecologic Oncology 2006;100:133-8.
Alberts 2008 {published data only}
  • Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival. Gynecologic Oncology 2008;109:174-81.
Bruzzone 1997 {published data only}
  • Bruzzone M, Rubagotti A, Gadducci A, Catsafados E. Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111patients. G.O.N.O. Gruppo Oncologic Nord Ovest. Journal of Gynecologic Oncology 1997;63(3):499-505.
Hall 2004 {published data only}
  • Hall GD, Brown JM, Coleman RE, Stead M, Metcalf KS, Peel KR, et al. Maintenance treatment with interferon for advanced ovarian cancer: results from the Northern and Yorkshire gynaecology group randomised phase III study. British Journal of Cancer 2004;91:621-6.
Windbichler 2000 {published data only}
  • Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. British Journal of Cancer 2000;82(6):1138-44.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Berek 2000 {published data only}
Cardamakis 1999 {published data only}
  • Cardamakis E, Ginopoulos P, Dimopoulos D, Avaraki M. Treatment of women with minimal residual ovarian cancer after cytoreductive surgery of stage III: Interferon alpha-2 plus carboplatin and cyclophosphamide versus carboplatin and cyclophosphamide. International Journal of Gynaecological Cancer 1999;9:20.
Sumrit 1998 {published data only}
  • Senapad S, Neungton S, Teerapakawong C, Piamsomboon S, Theerasakvichaya S, Suphanich A. Outcome of the ovarian epithelial Cancer stage I-II treated with cyclophosphamide plus cisplatinum or carboplatin. Siriraj Medical Journal 1998 October;50(10):925-32.

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Kosmidis 1997 {published data only}
  • Kosmidis P, Bafaloukos D, Skarlos D, Pavlidis N, Aravantinos G. Intraperitoneal (IP) Interferon A2b (INF) consolidation in ovarian cancer patients following carboplatin chemotherapy. European Journal of Cancer September 1997;33(8):88-9.
Zhyl'chuk 1998 {published data only}
  • Zhyl'chuk V, Alistratov OV, Vorontsova AL. [Increasing the efficacy of treating patients with extensive ovarian cancer by using laferon]. Lik Sprava [Ukranian] May 1998;3:117-9.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
ACS 2013
  • Anonymous. Survival rates for ovarian cancer, by stage. http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-survival-rates (accessed 31 March 2013) March 2013.
Berek 1985
  • Berek JS, Hacker NF, Lichenstein A. Intraperitoneal recombinant α-interferon for "salvage" immunotherapy in Stage III epithelial ovarian cancer:a Gynecology Oncology Group Study. Cancer Research 1985;45:4447-53.
Deeks 2001
  • Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG (editors). Systematic Reviews in Health Care: Meta-analysis in Context (2nd edition). London (UK): BMJ Publication Group, 2001.
Dunn 2006
Einhorn 1988
Epstein 1980
  • Epstein LB, Shen JT, Abele JS, Reese CC. Sensitivity of human ovarian carcinoma cells to interferon and other antitumor agents as assessed by an in vitro semi-solid agar technique. Annals of the New York Academy of Sciences 1980;350:228-44.
EUROCARE 2003
  • Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al. and the EUROCARE Working Group. EUROCARE - 3: survival of cancer patients diagnosed 1990-94 - results and commentary. Annals of Oncology 2003;14 Suppl 5:v61-118.
FIGO nomenclature, Rio de Janeiro 1988
  • Reprinted from Heintz A, Odicino F, Maisonneuve P, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. International Journal Gynecology and Obstetrics 2006;95(1):S163.
Freedman 1983
  • Freedman RS, Gutterman JU, Wharton JT, Rutledge FN. Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma. Journal of Biological Response Modifiers 1983;2:133-8.
GLOBOCAN 2002
  • Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. IARCPress, Lyon 2004.
Gresser 2002
Gresser 2007
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
Holschneider 2000
Jemal 2008
Jui-Tung 1992
  • Jui-Tung Chen, Katsuhiko Hasumi, Kazumasa Masubuchi. Interferon-α, interferon-γ and sizofiran in the adjuvant therapy in ovarian cancer — a preliminary trial. Biotherapy December 1992;5(4):275-80.
Maher 2007
Mandelli 1990
  • Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. New England Journal of Medicine 1990;322:1430-4.
Mei 2010
  • Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database of Systematic Reviews 2010;Issue 9:[DOI: 10, 1002/14651858.CD007414.pub2].
Mei 2011
  • Mei L, Chen H, Chen F, Feng D, Fang F. Maintenance bioimmunotherapy for epithelial ovarian cancer (Protocol). Cochrane Database of Systematic Reviews 2011;Issue 5:[DOI: 10.1002/14651858.CD009137].
Moserle 2008
Nardi 1990
  • Nardi M, Cognetti F, Pollera CF. Intraperitoneal recombinant α2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study. Journal of Clinical Oncology 1990;8:1036-41.
Parmar 1998
Pickel 1999
  • Pickel H, Lahousen M, Petru E, Stettner H, Hackl A, Kapp K, et al. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecology Oncology 1999;72:215-9.
Revman 5 [Computer program]
  • The Cochrane Collaboration. Review Manager (RevMan). The Cochrane Collaboration, Version 5.0. Copenhagen. The Nordic Cochrane Centre, The Cochrane Collaboration 2008.
Schroder 2004
Sorbe 2003
  • Sorbe B. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized controlled clinical trial comparing whole abdominal radiotherapy, chemotherapy and no further treatment. International Journal of Gynecological Cancer 2003;13:278-86.
Sourbier 2012
  • Sourbier C. Ovarian cancer: emerging molecular-targeted therapies. Biologics: Targets and Therapy 2012;6:147-54.
Tsuno 2009
Twombly 2007
Willemse 1990